Color Atlas of Neurology
.pdf
|
|
|
|
Myopathies |
|
|
Axon terminal |
|
|
|
|
Mitochon- |
|
Synaptic vesicle containing ACh* |
|
||
drion |
|
|
|
|
|
|
|
Basement |
|
|
|
|
|
membrane |
|
Complement-mediated AChR lysis |
|
|
|
|
|
Calcium channel autoantibodies |
|
|
|
|
|
(reduced ACh release) |
Muscle |
Muscle |
Normal |
AChR |
|
|
|
|
|
|
|||
Release of ACh |
|
|
|
|
and |
|
|
|
|
|
|
|
binding |
(ACh-effect |
|
Nerve |
|
|
AChR autoantibody |
Loss of AChR |
|
|
|
|
|
MG |
diminished) |
|
Peripheral |
|
Neuromuscular synapse–Pathogenesis |
||||
|
|
||||
|
|
|
|
LEMS |
|
|
|
|
Ptosis |
|
|
Faciopharyngeal |
|
Intravenous |
|
|
|
|
edrophonium chloride |
|
|||
weakness |
|
|
|
||
|
|
|
|
|
|
Exercise-induced muscle weakness |
|
Normal muscle strength (after |
|
||
|
|
|
|
edrophonium chloride) |
|
|
|
Myasthenia gravis |
|
|
|
Amplitude reduction (decrement |
|
Increase in amplitude |
|
||
from 1st to 5th stimulus) |
|
|
|
||
|
(increment > 3.5 times higher than baseline) |
|
|||
|
|
|
|
||
|
|
Low |
|
|
|
|
|
starting amplitude |
|
||
Repeated low-frequency stimulation |
|
|
|
||
(3 Hz, trapezius m., MG) |
|
|
|
|
|
*ACh = acetylcholine |
Repetitive nerve stimulation |
Repeated high-frequency stimulation |
343 |
||
(20 Hz, abductor digiti quinti m., LEMS) |
|
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Myopathies
Myositis
The myositides (inflammatory myopathies) are a heterogeneous group of disorders, causing three distinct clinical syndromes: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM).
|
! Pathogenesis |
|
|
|
|||
Muscle |
Most myositides found in the temperate zones |
||||||
mation and fibrosis and loss of muscle fibers. In |
|||||||
|
are autoimmune diseases of unknown cause, |
||||||
|
characterized histologically by muscle inflam- |
||||||
and |
PM, cytotoxic CD8+ T cells penetrate and damage |
||||||
muscle fibers |
( intramuscular cellular infil- |
||||||
Nerve |
trates). CD8+ T cell activation is induced by ab- |
||||||
normal expression of class I HLA antigens on the |
|||||||
|
|||||||
Peripheral |
surface of the muscle fibers, which are normally |
||||||
HLA-negative. DM is thought to be largely due to |
|||||||
|
|||||||
|
antibodies against blood vessels within muscle, |
||||||
|
which activate the complement system (mem- |
||||||
|
brane attack complex). Vascular endothelial |
||||||
|
damage ultimately leads to ischemia and death |
||||||
|
of muscle tissue ( perifascicular atrophy). In- |
||||||
|
flammatory T cells and macrophages migrate |
||||||
|
into muscle and cause further damage. IBM is of |
||||||
|
unknown pathogenesis. Infectious myositis may |
||||||
|
be due to bacteria, viruses, parasites, or fungi. |
||||||
|
! Syndromes |
|
|
|
|
||
|
Polymyositis (PM) begins with weakness of the |
||||||
|
proximal muscles of the lower limbs, which |
||||||
|
then progresses and slowly spreads to the upper |
||||||
|
limbs. The deltoid and neck flexor muscles are |
||||||
|
commonly involved. Dysphagia may be present. |
||||||
|
The involved muscles eventually become |
||||||
|
atrophic. In overlap syndrome, myositis appears |
||||||
|
together |
with |
another autoimmune |
disease, |
|||
|
e. g., progressive systemic |
sclerosis, |
systemic |
||||
|
lupus erythematosus, rheumatoid arthritis, pol- |
||||||
|
yarteritis nodosa, polymyalgia rheumatica, or |
||||||
|
Sjögren syndrome. Myalgia is often the major |
||||||
|
symptoms in patients with PM, as also in |
||||||
|
patients |
with |
hypereosinophilia |
syndrome |
|||
|
(Churg–Strauss |
syndrome) |
or |
eosinophilic |
|||
|
fasciitis (Shulman disease). |
|
|
|
|||
|
Dermatomyositis (DM) progresses more rapidly |
||||||
|
than PM and is distinguished from it mainly by |
344the bluish-red or purple (heliotrope) rash found on exposed areas of the skin (eyelids, cheeks,
neck, chest, knuckles, and extensor surfaces of
the limbs). Small hemorrhages and telangiectasias are found in the nailbeds; affected children may have subcutaneous calcium deposits. Cancer accompanies DM six times more frequently than PM; DM is also associated with scleroderma and mixed connective tissue disease.
Inclusion body myositis (IBM) is characterized by distal (sometimes asymmetric) weakness and muscle atrophy, mainly in the lower limbs (plantar flexors), with early loss of the quadriceps reflexes. There are both sporadic and hereditary forms of IBM (see also p. 252).
! Diagnosis
The myositides are diagnosed by history and physical examination, elevated serum concentration of sarcoplasmic enzymes (particularly CK-MM), and characteristic findings on EMG and muscle biopsy. Muscle atrophy can also be assessed with various imaging techniques (CT, MRI, ultrasonography). The presence of antibodies in association with a connective tissue disease may be relevant to the diagnosis (p. 180).
! Treatment
PM and DM are treated by immune suppression, e. g., with corticosteroids, azathioprine, or intravenous gammaglobulin (ivig). Physical therapy is begun once the patient’s condition has stabilized. IBM may respond to intravenous immunoglobulin therapy.
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Myopathies
Cervical muscle weakness
Proximal muscle weakness and atrophy
Ischemic lesion of muscle fiber
Perifascicular atrophy (DM; cross section of muscle fiber)
Lymphomonocytic infiltrate in muscle, vessel (PM, cross section of muscle fiber)
Lid edema
Facial erythema
Proximal muscle weakness
Telangiectasis,
Polymyositis (PM) hemorrhage (nailbed)
Erythema in joint region (extensor side)
Dermatomyositis (DM)
Distal muscle atrophy
Bleeding
Inclusion body myositis (IBM) |
Butterfly rash (lupus erythematosus) |
Peripheral Nerve and Muscle
345
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Neuromuscular Disorders
|
Muscle Pain (Myalgia) |
pain induced by normally nonpainful stimuli |
|||||
|
and is explained by the sensitization of nocicep- |
||||||
|
|
|
|
|
|
||
|
Myalgia is an aching, cramping, or piercing pain |
tors by pain-related substances such as brady- |
|||||
|
in muscle. It is triggered by stimulation of noci- |
kinin, serotonin, and prostaglandin. A “charley- |
|||||
|
ceptors (p. 108). Pressure or traction on a muscle |
horse” is a type of myalgia that normally begins |
|||||
|
causes myalgia that subsides once the mechani- |
8–24 hours after muscle overuse (simultaneous |
|||||
|
cal stimulus is removed, while inflammatory |
stretching and contraction) and lasts 5–7 days. It |
|||||
|
and other lesions in muscle cause persistent and |
is caused by an inflammatory reaction to muscle |
|||||
|
gradually increasing myalgia. Muscle ischemia |
fiber damage. Myalgia can be triggered by dis- |
|||||
Muscle |
and/or metabolic dysfunction are reflected by |
orders whose primary pathology lies anywhere |
|||||
myalgia occurring only during muscle activity. |
in the nervous system (peripheral nerve, spinal |
||||||
|
|||||||
|
Myalgia includes allodynia, which is defined as |
cord, brain). |
|||||
and |
! Causes of Myalgia |
|
|
|
|||
|
|
|
|
||||
Nerve |
|
|
|
|
|||
|
Type of Myalgia |
Selected Causes |
|
||||
|
|
|
|
|
|||
|
Localized myalgia |
" |
|
|
|||
Peripheral |
|
" |
Hematoma |
Trauma, coagulopathy |
|
||
|
" |
Myositis |
" Infectious: Streptococcal infection, trichinosis, influenza, epidemic pleurodynia. Non- |
||||
|
|
|
|
|
infectious: Nodular focal myositis, eosinophilic fasciitis, sarcoidosis, myositis ossifi- |
||
|
|
|
|
|
cans |
|
|
|
|
" |
Ischemic |
" Arteriosclerosis (intermittent claudication), embolism |
|||
|
|
" |
Toxic-metabolic |
" Acute alcoholic myopathy, metabolic myopathy (pp. 402, 405) |
|||
|
|
" |
Overactivity |
" Stiff-man syndrome, neurogenic myotonia, tetanus, strychnine poisoning, amyo- |
|||
|
|
" |
|
" |
trophic lateral sclerosis, tetany |
|
|
|
|
Exercise- |
Metabolic myopathy, arteriosclerosis, physical exertion |
||||
|
|
" |
induced |
" |
|
|
|
|
|
Parkinsonian |
Rigidity |
|
|||
|
|
" |
Muscle spasm |
" Polyneuropathy, metabolic disorder (electrolyte imbalance, uremia, thyroid dysfunc- |
|||
|
|
" |
|
" |
tion) |
|
|
|
|
Pain at rest |
Restless legs syndrome, painful legs and moving toes syndrome |
||||
|
|
Generalized myalgia |
|
|
|
||
|
|
" |
Myositis |
" |
Polymyositis/dermatomyositis (p. 344) |
||
|
|
" |
Toxic-metabolic |
" Hypothyroidism, medications2, mitochondrial myopathy (pp. 340, 402, 405) |
|||
|
|
" |
Other |
" Polymyalgia rheumatica, amyloidosis, osteomalacia, Guillain–Barré syndrome, |
|||
|
|
|
|
|
porphyria, hypothyroidism, corticosteroid withdrawal, fibromyalgia |
||
|
|
|
|
|
|
|
(Adapted from Layzer, 1994)
1 E.g., emetine, lovastatin, and ε-aminocaproic acid.
|
Rhabdomyolysis |
stroke, delirium tremens, status epilepticus), by |
|
toxic substances (see below), and by infectious |
|
|
|
|
|
Local or generalized damage to skeletal muscle |
disease (bacterial sepsis, influenza, coxsack- |
|
can cause myoglobinuria and an elevated serum |
ievirus or echovirus infection). |
|
concentration of creatine kinase, usually accom- |
|
|
panied by the acute onset of proximal or diffuse |
Malignant Hyperthermia (MH) |
|
weakness, with myalgia, muscle swelling, and |
|
|
|
|
|
general manifestations including nausea, vomit- |
This life-threatening disorder of skeletal muscle |
|
ing, headache, and sometimes fever. The urine |
function is characterized by hyperthermia, |
|
may be discolored at the onset of symptoms or |
muscle rigidity, hyperhidrosis, tachycardia, cya- |
|
several hours later. Rhabdomyolysis can be |
nosis, lactic acidosis, hyperkalemia, massive |
|
||
|
caused by certain types of myopathy (e. g., poly- |
elevation of the serum creatine kinase concen- |
346 |
myositis, central core disease, metabolic my- |
tration, and myoglobinuria. It is induced by an- |
|
opathies; pp. 402, 405), by muscle strain or |
esthetic agents such as halothane and succinyl- |
|
trauma (long-distance walking or running, heat |
choline. The predisposition to MH is inherited as |
|
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Neuromuscular Disorders
an autosomal dominant trait (gene loci: 19q13.1, 17q11–24, 7q12.1, 5p, 3q13.1, 1q32). The creatine kinase level may be chronically elevated in susceptible individuals, who can be identified with an in vitro contracture test performed in specialized laboratories. Persons suffering from central core disease, multicore disease, and King–Denborough syndrome (dwarfism, skeletal anomalies, ptosis, high palate) are also at risk for MH. Treatment: dantrolene.
Malignant neuroleptic syndrome clinically resembles MH; unlike MH, however, it is usually of subacute onset (days to weeks), it is not hereditary, and it is triggered by psychotropic drugs (haloperidol, phenothiazines, lithium). Malignant neuroleptic syndrome can also be induced by abrupt withdrawal of dopaminergic agents in patients with Parkinson disease.
Toxic Neuromuscular Syndromes
The muscle fiber lesions regress if the responsible substance is eliminated in timely fashion (Table 75, p. 405).
Myopathy in Endocrine Disorders
Hyperthyroidism or hypothyroidism, hyperparathyroidism, Cushing syndrome, steroid myopathy, and acromegaly all cause proximal weakness, while Addison disease and primary hyperaldosteronism usually cause generalized weakness. Timely correction of the endocrine disorder or withdrawal of steroid drugs is usually followed by improvement.
Critical Illness Polyneuropathy (CIP)
and Critical Illness Myopathy (CIM)
Sepsis is the most common cause not only of encephalopathy (see p. 312) but also of CIP and CIM. CIP is an acute, reversible, mainly axonal polyneuropathy. It causes distal, symmetric weakness with prominent involvement of the muscles of respiration, resulting in prolonged ventilator dependence and delayed mobilization. CIM causes generalized weakness. The clinical differentiation of CIM and CIP is difficult and often requires muscle biopsy.
Paraneoplastic Syndromes
(Table 76, p. 406)
Distant neoplasms can affect not only the CNS (see p. 388) but also the PNS and skeletal muscle. Remarkably, paraneoplastic syndromes sometimes appear months or years before the underlying malignancy becomes clinically manifest. Paraneoplastic neuromuscular syndromes typically present with marked weakness of subacute onset (i.e., developing over several days or weeks).
Peripheral Nerve and Muscle
347
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
348
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
4 Diagnostic Evaluation
!History and Physical Examination
!Additional Studies
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Diagnostic Evaluation
350
History and Physical Examination
A detailed description of diagnostic evaluation procedures can be found in the textbooks listed on p. 409. The goals of history-taking, physical examination, and additional testing (if necessary) are:
!Data collection (manifestations of disease)
!Localization of the lesion
!Provision of an etiological diagnosis
"Data Collection
The diagnostic process begins with the history and physical examination. The history provides information about the patient’s experience of illness, the temporal course of symptom development, and potentially relevant familial, social, occupational, and hereditary factors. An inaccurate or incomplete history is a frequent cause of misdiagnosis.
History. The physician engages the patient in a structured conversation about the manifestations of the illness. The physician must remember that the patient is the “expert” in this situation, as the patient alone knows what is troubling him (though perhaps helpful information can also be obtained from a close relative or friend). The physician aims to obtain accurate information on the nature, location, duration, and intensity of the symptoms by listening patiently and asking directed questions in an atmosphere of openness and trust. Questionnaires, computer programs, and ancillary personnel cannot be used for primary his- tory-taking, as they do not enable the construction of a trusting physician–patient relationship (though they may provide useful additional information at a later stage). Some important elements of the case history are as follows.
!Nature of symptoms. The physician must ascertain, by detailed questioning if necessary, that he understands the patient’s complaints in the same sense that the patient means to convey. “Blurred vision” may mean diplopia, “dizziness” may mean gait ataxia, “headache” may mean hemicrania, “numbness” may mean paresthesia—but patients may use all of these terms with other meanings as well.
!Severity of symptoms. Quality and intensity of symptoms, activities with which they interfere.
!Onset of symptoms. When, where, and over what interval of time did the symptoms arise?
!Time course of symptoms. How did they develop? Are they constant or variable? Are there any exacerbating or alleviating factors?
!Accompanying symptoms, if present.
!Past history of similar symptoms.
!Previous illnesses and their outcome.
!Social, occupational, and family history.
!Medications, smoking, alcohol abuse, substance abuse, toxic exposures.
!Previous diagnostic studies and treatment.
!Information from third parties may be needed for patients with aphasia, confusion, demen-
tia, or impairment of consciousness.
Physical examination. The general and neurological physical examination may yield important clues to the disease process, but only if the examiner has the requisite knowledge of the underlying principles of (neuro-)anatomy, (neuro-)physiology, and (neuro-)pathology. The examination is guided by the case history, i.e., the patient’s complaints and general physical condition determine what the examiner looks for in the examination. The unselective, “shotgun” application of every possible technique of neurological examination in every patient is not only a waste of time and money; it generally only creates confusion rather than clarifying the search for the diagnosis. The neurological examination of small children, patients with personality changes or mental illness, and unconscious patients poses special challenges.
Important elements of the neurological examination include:
!Inspection. Dress, appearance, posture, movements, speech, gestures, facial expression.
!Mental Status. Orientation (to person, place, and time), attention, concentration, memory, thought processes, language function, level of consciousness.
!Cranial nerves. Olfaction, pupils, visual fields, eyegrounds, eye movements, facial movement, facial sensation, hearing, tongue movements, swallowing, speaking, reflexes.
!Motor function. Muscular atrophy/hypertrophy, spontaneous movements, coordination, paresis, tremor, dystonia, muscle tone.
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
History and Physical Examination
!Reflexes (p. 40).
!Sensory function. The findings of sensory testing are heavily influenced by the patient’s “sensitivity” and ability to cooperate. Vague sensory abnormalities without other neurological deficits are difficult to classify; their interpretation requires a good knowledge of the underlying neuroanatomy (pp. 32ff, 106f).
!Posture, station, and gait. The observation and testing of posture, station, and gait provides important information about a possible motor deficit (p. 42 ff).
!Autonomic function. The patient is questioned about bladder function, bowel movement/control, sexual function, blood pressure, cardiac function, and sweating, and is examined as needed.
"Localization of the Lesion
The findings of the history and physical examination findings are then related to dysfunction of a particular neuroanatomical structure(s) (p. 2 ff) or neurophysiological process (p. 40 ff); the site of the patient’s problem is thus localized (topical diagnosis).
" Provision of an Etiological Diagnosis
Once the site of the problem is localized, it must be determined whether it is due to a structural lesion (e. g., hemorrhage, nerve compression, or infection) or a functional disturbance (e. g.,
epileptic seizure, migraine, or Parkinson disease). The line between structural and functional pathology is not perfectly defined, as there is constant interaction between these two levels; at the same time, considerations of etiology and pathogenesis also influence data interpretation. The diagnostic process ideally ends in the diagnosis of a specific disease entity (nosological diagnosis).
Additional Diagnostic Studies
The clinical diagnosis may be considered firmly established by the history and physical examination alone in many cases, e. g., migraine or Parkinson disease. Additional diagnostic studies are merely confirmatory and are generally not needed unless doubt arises as to the diagnosis, e. g., if an epileptic seizure or new type of headache should appear.
Additional studies are needed, however, if there is no other way to decide among several diagnostic possibilities remaining after thorough his- tory-taking and physical examination. The number and type of studies needed differ from case to case. Studies that are costly or fraught with nonnegligible risk should never be ordered except to answer a clearly stated diagnostic question. The potential benefits of a proposed study must always be weighed against its risks and cost.
" Laboratory Tests
Table 77, p. 407
Diagnostic Evaluation
351
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.
Diagnostic Evaluation
Neurophysiological and Neuropsychological Tests
" Neurophysiological Tests
Test/Purpose |
Risks |
Comments |
|
|
|
|
|
Electroencephalography: To assess elec- |
Surface electrodes: none |
Sphenoid, subdural or depth re- |
|
trical activity of the brain1 |
Needle electrodes: infec- |
cording3 for special questions relevant |
|
|
tion |
to the (preoperative) diagnostic eval- |
|
|
Induction of seizures by |
uation of epilepsy |
|
|
|
||
|
provocative methods2 |
|
|
Evoked potentials (EPs): |
|
|
|
! VEPs4: Study of optic nerve, optic |
! |
None |
! Used mainly to diagnose prechias- |
chiasm and optic tract |
|
|
matic lesions |
! AEPs5: Study of peripheral and cen- |
! |
None |
! Used mainly for diagnosis of multi- |
tral segments of the auditory path- |
|
|
ple sclerosis, tumors of the poste- |
way6 |
|
|
rior cranial fossa, brain stem le- |
|
|
|
sions causing coma or brain death, |
! SEPs7: Study of somatosensory sys- |
|
|
and intraoperative monitoring |
! |
None |
! Used to assess proximal peripheral |
|
tems8 |
|
|
nerve lesions (plexus, roots) and |
|
|
|
spinal cord or parietal lobe lesions |
! MEPs9: Study of corticospinal |
! |
May induce epileptic |
! Pyramidal tract lesions, motor neu- |
motor pathway |
|
seizures. Contraindica- |
ron lesions, root compression, |
|
|
tions: cardiac |
plexus lesions, stimulation of deep |
|
|
pacemakers, metal |
nerves, differential diagnosis of |
|
|
prostheses in the target |
psychogenic paresis |
|
|
area, pregnancy, un- |
|
|
|
stable fractures |
|
Electromyography: Study of electrical |
Contraindication: |
Provides information on motor unit |
|
activity in muscle |
coagulopathy. Risk of in- |
disorders in patients with peripheral |
|
|
jury in special studies11 |
nerve lesions or myopathies. Not dis- |
|
|
|
|
ease-specific. Disposable needles |
|
|
|
should be used to prevent spread of |
|
|
|
infectious disease10 |
Electroneurography: Measurement of |
Needle recordings con- |
Localization (proximal, distal, conduc- |
|
motor and sensory conduction veloci- |
traindicated in patients |
tion block) and classification (axonal, |
|
ties. |
with coagulopathy |
demyelinating) of peripheral nerve le- |
|
|
|
|
sions12 |
Electro-oculography: To record and |
Caloric testing with water |
Diagnosis and localization of periph- |
|
assess eye movements and/or nystag- |
contraindicated in patients |
eral and central vestibular lesions. |
|
mus |
with perforated eardrums |
Differentiation of saccades |
|
|
|
|
|
1 For assessment of epilepsy, localized pathology (neoplasm, trauma, meningoencephalitis, infarct) or generalized pathology (intoxication, hypoxia, metabolic encephalopathy, Creutzfeldt–Jakob disease, coma, brain death), for sleep analysis (polysomnography), or to monitor the course of such conditions. 2 Photostimulation, hyperventilation, sleep, sleep withdrawal. 3 For diagnostic assessment before epilepsy surgery, in specialized centers.
4 Visual EPs. 5 Acoustic EPs. 6 Peripheral nerve and cochlear lesions are mainly studied audiometrically, and peripheral and central disorders by electro-oculography or posturography. 7 Somatosensory EPs. 8 Functional assessment of sensory pathways (p. 104) by tibial, median, ulnar, and trigeminal nerve stimulation. 9 Motor EPs. 10 Particularly Creutzfeldt–Jakob disease, hepatitis, AIDS. 11 Examples: Pneumothorax in study of the serratus anterior m., perforation of the rectal wall in study of the anal sphincter. 12 F-wave measurement for localization of proximal nerve damage, H-reflex in S1 syndrome.
|
" Neuropsychological Tests |
tion suggest the possibility of mental illness or |
|
of mental dysfunction due to neurological dis- |
|
|
Comprehensive testing of cognitive function, |
|
|
ease. Objectives: Accurate detection and effec- |
|
352 |
behavior, and affective processes, perhaps in |
tive monitoring, prognostication, identification |
|
collaboration with a neuropsychologist, is re- |
of etiology, and treatment of mental disorders |
|
quired when the history and physical examina- |
(p. 122 ff). |
|
Rohkamm, Color Atlas of Neurology © 2004 Thieme
All rights reserved. Usage subject to terms and conditions of license.